In summary, our findings of ERK1/2-mediated Ser-233 phosphorylation of DHPS not only expand our current understanding of the mechanism underlying the regulation of the hypusination pathway, but also provide new insights into the cellular processes affected by ERK1/2 pathway inhibition, which could be used as a therapeutic strategy for pathological conditions such as cancer. The gene discussed is MAPK3; the disease is cancer.